1. Home
  2. TOI vs LYRA Comparison

TOI vs LYRA Comparison

Compare TOI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOI
  • LYRA
  • Stock Information
  • Founded
  • TOI 2007
  • LYRA 2005
  • Country
  • TOI United States
  • LYRA United States
  • Employees
  • TOI N/A
  • LYRA N/A
  • Industry
  • TOI Medical/Nursing Services
  • LYRA Medical/Dental Instruments
  • Sector
  • TOI Health Care
  • LYRA Health Care
  • Exchange
  • TOI Nasdaq
  • LYRA Nasdaq
  • Market Cap
  • TOI 20.1M
  • LYRA 18.0M
  • IPO Year
  • TOI N/A
  • LYRA 2020
  • Fundamental
  • Price
  • TOI $0.25
  • LYRA $0.18
  • Analyst Decision
  • TOI Strong Buy
  • LYRA Buy
  • Analyst Count
  • TOI 1
  • LYRA 5
  • Target Price
  • TOI $2.50
  • LYRA $4.50
  • AVG Volume (30 Days)
  • TOI 187.1K
  • LYRA 2.0M
  • Earning Date
  • TOI 11-13-2024
  • LYRA 11-12-2024
  • Dividend Yield
  • TOI N/A
  • LYRA N/A
  • EPS Growth
  • TOI N/A
  • LYRA N/A
  • EPS
  • TOI N/A
  • LYRA N/A
  • Revenue
  • TOI $361,067,000.00
  • LYRA $1,471,000.00
  • Revenue This Year
  • TOI $29.17
  • LYRA $13.99
  • Revenue Next Year
  • TOI $16.43
  • LYRA N/A
  • P/E Ratio
  • TOI N/A
  • LYRA N/A
  • Revenue Growth
  • TOI 23.31
  • LYRA 3.37
  • 52 Week Low
  • TOI $0.23
  • LYRA $0.18
  • 52 Week High
  • TOI $2.50
  • LYRA $6.79
  • Technical
  • Relative Strength Index (RSI)
  • TOI 39.10
  • LYRA 30.57
  • Support Level
  • TOI $0.25
  • LYRA $0.26
  • Resistance Level
  • TOI $0.30
  • LYRA $0.28
  • Average True Range (ATR)
  • TOI 0.04
  • LYRA 0.02
  • MACD
  • TOI -0.00
  • LYRA -0.01
  • Stochastic Oscillator
  • TOI 19.31
  • LYRA 0.35

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: